What question did this study set out to answer?

This research aims to develop a prognostic framework based on glycosylation for bladder cancer and validate the role of ALG3 as a therapeutic target.

June 9, 2026Discover OncologyOpen Access

Integrative multi-omics identifies a glycosylation-based prognostic framework and nominates ALG3 for targeted therapy in bladder cancer

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial identifies a glycosylation-related prognostic model in bladder cancer, suggesting targeted therapy with ALG3.

This research aims to develop a prognostic framework based on glycosylation for bladder cancer and validate the role of ALG3 as a therapeutic target.
Used clinical and transcriptomic data from The Cancer Genome Atlas (TCGA) and glycosylation-related genes from GSEA.
Constructed a prognostic signature using LASSO regression and validated it with ROC curves and survival analyses.
Performed experimental validation for the gene ALG3.
Established a 9-glycosylation-mRNA signature that stratifies bladder cancer patients into distinct risk groups with significant overall survival differences.
Achieved robust predictive accuracy with AUC, independent of common clinicopathological factors.
Confirmed elevated expression of ALG3 in tumors, demonstrating its role in promoting cancer cell proliferation.

Feng et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark